Journal List > J Korean Ophthalmol Soc > v.54(2) > 1009608

Jung, Lee, and Yim: A Case of Inferior Rectus Muscle Enlargement after Taking Sildenafil Citrate

Abstract

Purpose

Sildenafil citrate was developed to treat angina, but was found to also inhibit PDE in the corpus callosum and is now widely used to treat impotence. We report a case of enlargement of the inferior rectus muscle after sildenafil citrate ingestion.

Case summary

A 58-year-old male presented with binocular diplopia which started 2 weeks prior. He had no underlying disease. The patient had taken sildenafil citrate on 3 different occasions 2 weeks prior, and 2 days after his first ingestion, his right conjunctiva was injected and binocular diplopia started. On the first visit, he showed 16 PD hypotropia of the right eye with limitation of motion at upgaze. The MRI scan showed enlargement and enhancement of the inferior rectus muscle, and 50 mg of prednisone was prescribed. The amount of hypotropia decreased to 8 PD 2 weeks later.

Conclusions

Enlargement of extraocular muscle caused by sildenafil citrate ingestion has not been reported in Korea, and related mechanisms are yet to be researched. Additional case reports and research are necessary in the future.

References

1. Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol. 1999; 44:153–62.
crossref
2. Sivaswamy L, Vanstavern GP. Ischemic optic neuropathy in a child. Pediatr Neurol. 2007; 37:371–2.
crossref
3. Tripathi A, O'Donnell NP. Branch retinal artery occlusion; another complication of sildenafil. Br J Ophthalmol. 2000; 84:934–5.
crossref
4. Donahue SP, Taylor RJ. Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). Am J Ophthalmol. 1998; 126:476–7.
crossref
5. Jang YS, Ahn GS, Kim SD. Retinal hemorrhage associated with viagra (sildenafil citrate). J Korean Ophthalmol Soc. 2002; 43:1340–4.
6. Fraunfelder FW, Pomeranz HD, Egan RA. Nonarteritic anterior ischemic optic neuropathy and sildenafil. Arch Ophthalmol. 2006; 124:733–4.
crossref
7. Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf. 2009; 32:1–18.
8. Lee WJ, Seong M. Bilateral simultaneous acute angle closure glaucoma following sexual intercourse aided by sildenafil citrate. J Korean Ophthalmol Soc. 2011; 52:1123–7.
crossref
9. Lee JS, Oum BS, Choi CH, Kim HJ. Clinical study of the idiopathic orbital myositis. J Korean Ophthalmol Soc. 1999; 40:1109–15.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239–45.
crossref
11. Kim CH, Lim JY, Ahn JH, Jang JW. A case of idiopathic orbital myositis involving all extraocular muscles of both eyes. J Korean Ophthalmol Soc. 2001; 42:1615–20.
12. Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology. 1997; 104:402–8.
crossref
13. Weinstein GS, Dresner SC, Slamovits TL, Kennerdell JS. Acute and subacute orbital myositis. Am J Ophthalmol. 1983; 96:209–17.
crossref
14. Subramanian PS, Kerrison JB, Calvert PC, Miller NR. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol. 2003; 121:1335–6.
crossref
15. Phillips PM, Newman SA. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol. 2008; 126:137–9.
crossref

Figure 1.
The patient shows 16 PD of right hypotropia and upper gaze limitation.
jkos-54-382f1.tif
Figure 2.
Axial (A), coronal (B), sagittal (C, D) M RI images show enlargement and enhancement of the inferior rectus muscle of the right eye. There is no enlargement of the extraocular muscles of the left eye.
jkos-54-382f2.tif
Table 1.
The Naranjo adverse drug reaction probability scale
  Yes No Do not know Score
1. Are there previous conclusive reports on this reaction? +1 0 0 0
2. Did the adverse event occur after the suspected drug was administered? +2 −1 0 +2
3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? +1 0 0 +1
4. Did the adverse reaction reappear when the drug was readministered? +2 −1 0 0
5. Are there alternative causes (other than the drug) that could have on their own caused the reaction? −1 +2 0 +2
6. Did the reaction reappear when a placebo was given? −1 +1 0 0
7. Was the blood detected in the blood (or other fluids) in concentrations known to be toxic? +1 0 0 0
8. Was the reaction more severe when the dose was increased or less severe when the dose was decreased? +1 0 0 0
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 0
10. Was the adverse event confirmed by any objective evidence? +1 0 0 +1
Assessment score: Total 6

Definite ≥ 9; Probable 5-8; Possible 1-4; doubtful ≤ 0.

TOOLS
Similar articles